NASDAQ:GBT

Global Blood Therapeutics (GBT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $68.49
▼
$68.49
50-Day Range: $68.07
▼
$68.49
52-Week Range: $21.65
▼
$73.02

Volume: 74 shs
Average Volume: 2.07 million shs
Market Capitalization: $4.62 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Financials Institutional Ownership Headlines Options Chain SEC Filings Short Interest Social Media Sustainability

About Global Blood Therapeutics (NASDAQ:GBT) Stock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

July 28, 2023 | finance.yahoo.com

PFE Mar 2024 32.500 call

June 17, 2023 | benzinga.com

Gout Therapeutics Market Challenges, Drivers, Growth Opportunities, and Major Company Profiles 2023

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

June 14, 2023 | finance.yahoo.com

Global Patient Blood Management Market to Reach $23.6 Billion by 2030

June 12, 2023 | finance.yahoo.com

Global Lymphoma Therapeutics Market Report 2023: Sector is Expected to Reach $24.9 Billion by 2029 at a CAGR of 7.8%

June 11, 2023 | finance.yahoo.com

Global Health Study Validates Biospectal OptiBP Mobile Blood Pressure Measurement App Accuracy Across Diverse Settings

June 7, 2023 | bizjournals.com

Ted Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-pays

June 6, 2023 | finance.yahoo.com

GBT Received a Notice of Allowance for its Microchip Reliability Verification and Auto-Correction Patent Application

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

June 4, 2023 | es-us.finanzas.yahoo.com

The Global Non-insulin Diabetes Therapeutics Market

May 23, 2023 | msn.com

Pfizer Announces $5.4 Billion Deal to Acquire Global Blood Therapeutics

May 17, 2023 | marketwatch.com

(2023-2030) Anemia Drugs Market Size, Share and Trend Analysis Report, Worldwide Opportunities, Demand Forecast

May 11, 2023 | marketwatch.com

Artificial Blood Market, Global Outlook and Forecast 2023-2029

May 5, 2023 | marketwatch.com

2030 Blood Cancer Therapeutics Market Forecast: Positive Growth Trajectory Ahead

May 5, 2023 | finance.yahoo.com

Rare Disease Therapeutics Global Market Report 2023: Increasing Number of Patients with Rare Diseases Bolsters Growth

May 5, 2023 | finance.yahoo.com

Monoclonal Antibody Therapeutics Market to Surpass US$ 534.26 Billion by 2030, Says Coherent Market Insights (CMI)

May 5, 2023 | marketwatch.com

Metabolic Disorder Therapeutics Market 2023 Set to Growth Highest CAGR and Revenue by 2030

May 4, 2023 | finance.yahoo.com

Global Antimicrobial Therapeutics Market Report 2023-2027: Sector to Grow by $51.4 Billion at a 5.63% CAGR

April 27, 2023 | finance.yahoo.com

Prostate Cancer Therapeutics Global Market Report 2023: Launch of Emerging Novel Therapies Brings Momentum

April 25, 2023 | finance.yahoo.com

GBT IP Technology Portfolio and Other Updates

April 20, 2023 | technews.tmcnet.com

GBT's intelligent, human vitals qTerm device patent received an issue notification

April 19, 2023 | finance.yahoo.com

Glycobiology: Global Markets for Diagnostics and Therapeutics

April 13, 2023 | finance.yahoo.com

GBT’s Database Management System, Continuation Patent Received Notice of Allowance

April 9, 2023 | finance.yahoo.com

Global Genetic Disorders Partnering 2023: Trends, Financials and Players from Every Deal Since 2016

March 21, 2023 | marketwatch.com

2023-2028 Anemia Drugs Market: Growth Investments and Opportunities by Top Players

March 21, 2023 | tmcnet.com

GBT Filed Patent Continuation Application for its Automatic Correction of Integrated Circuits Connectivity Mismatches Patent

March 19, 2023 | marketwatch.com

Global Acquired Orphan Blood Diseases Therapeutics Market Outlook and Major Regions’ Development Status By VMReports

See More Headlines

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Company Calendar

Last Earnings: 11/04/2021
Today: 9/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GBT
CUSIP: N/A
CIK: 1629137
Web: www.gbt.com
Phone: (650) 741-7700
Fax: N/A
Employees: 457
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($5.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-303,090,000.00
Net Margins: -137.30%
Pretax Margin: -137.01%
Return on Equity: -170.37%
Return on Assets: -39.24%

Debt

Debt-to-Equity Ratio: 4.92
Current Ratio: 6.88
Quick Ratio: 6.17

Sales & Book Value

Annual Sales: $194.75 million
Price / Sales: 23.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.05 per share
Price / Book: 22.46

Miscellaneous

Outstanding Shares: 67,476,000
Free Float: 64,170,000
Market Cap: $4.62 billion
Optionable: Optionable
Beta: 0.45

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Ted W. Love M.D. (Age 63)
Pres, CEO & Director
Comp: $1.06M

Mr. Jeffrey S. Farrow (Age 60)
CFO & Principal Accounting Officer
Comp: $672.67k

Ms. Jung E. Choi (Age 52)
Chief Bus. & Strategy Officer
Comp: $645k

Mr. David L. Johnson (Age 53)
Chief Commercial Officer
Comp: $661.5k

Dr. Kim Smith-Whitley M.D. (Age 61)
Exec. VP and Head of R&D
Comp: $654k

Dr. David R. Phillips
Founder & Advisor

Dr. Matthew P. Jacobson Ph.D.
Founder & Advisor

Dr. Andrej Sali Ph.D.
Founder & Advisor

Ms. Nazila Habibizad (Age 59)
Exec. VP of Operations

Stephanie Yao
Sr. Director of Corp. Communications & Investor Relations

Key Competitors

View All Competitors

GBT Stock - Frequently Asked Questions

How were Global Blood Therapeutics' earnings last quarter?: Global Blood Therapeutics, Inc. (NASDAQ:GBT) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company earned $52.05 million during the quarter, compared to analyst estimates of $53.69 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative trailing twelve-month return on equity of 170.37%. Global Blood Therapeutics's revenue for the quarter was up 41.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.97) EPS.
What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?: 20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.
What other stocks do shareholders of Global Blood Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).
When did Global Blood Therapeutics IPO?: (GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?: Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."
What is Global Blood Therapeutics' stock price today?: One share of GBT stock can currently be purchased for approximately $68.49.
How much money does Global Blood Therapeutics make?: Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.62 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis.
How many employees does Global Blood Therapeutics have?: The company employs 457 workers across the globe.
How can I contact Global Blood Therapeutics?: Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com.

This page (NASDAQ:GBT) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Global Blood Therapeutics (GBT) Stock Forecast, Price & News

About Global Blood Therapeutics (NASDAQ:GBT) Stock

GBT Stock News Headlines

GBT Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GBT Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info